使用砹 - 211和铋 - 213的α粒子放射免疫疗法。 - Suppr

Alpha-particle radioimmunotherapy with astatine-211 and bismuth-213.

作者信息

Lucignani Giovanni

机构信息

Institute of Radiological Sciences, University of Milan, Unit of Nuclear Medicine, Hospital San Paolo, Via Antonio di Rudinì 8, Milan, Italy.

出版信息

Eur J Nucl Med Mol Imaging. 2008 Sep;35(9):1729-33. doi: 10.1007/s00259-008-0856-4.

DOI:10.1007/s00259-008-0856-4

PMID:18542953

Abstract

摘要

相似文献

Alpha-particle radioimmunotherapy with astatine-211 and bismuth-213.

Eur J Nucl Med Mol Imaging. 2008 Sep;35(9):1729-33. doi: 10.1007/s00259-008-0856-4.

Radioimmunotherapy with alpha-particle emitting radionuclides.

Q J Nucl Med Mol Imaging. 2004 Dec;48(4):289-96.

Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.

Acta Oncol. 1996;35(3):373-9. doi: 10.3109/02841869609101654.

Astatine-211: production and availability.

Curr Radiopharm. 2011 Jul;4(3):177-85. doi: 10.2174/1874471011104030177.

Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated α-Radioimmunotherapy with At-MX35-F(ab'): Influence of Absorbed Tumor Dose and Effect on Long-Term Survival.

J Nucl Med. 2017 Apr;58(4):598-604. doi: 10.2967/jnumed.116.178327. Epub 2016 Sep 29.

Potential and pitfalls of therapy with alpha-particles.

J Nucl Med. 2005 Aug;46(8):1254-5.

211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.

J Nucl Med. 2005 Dec;46(12):2061-7.

Vascular-targeted radioimmunotherapy with the alpha-particle emitter 211At.

Radiat Res. 2002 Jun;157(6):633-41. doi: 10.1667/0033-7587(2002)157[0633:vtrwta]2.0.co;2.

Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia.

Recent Results Cancer Res. 1996;141:101-22. doi: 10.1007/978-3-642-79952-5_7.

An Appendix of Radionuclides Used in Targeted Alpha Therapy.

J Med Imaging Radiat Sci. 2019 Dec;50(4 Suppl 1):S58-S65. doi: 10.1016/j.jmir.2019.06.051. Epub 2019 Aug 16.

引用本文的文献

Towards elucidating the radiochemistry of astatine - Behavior in chloroform.

Sci Rep. 2019 Nov 4;9(1):15900. doi: 10.1038/s41598-019-52365-5.

Combination Radioimmunotherapy Approaches and Quantification of Immuno-PET.

Nucl Med Mol Imaging. 2016 Jun;50(2):104-11. doi: 10.1007/s13139-015-0392-7. Epub 2016 Jan 26.

Molecular targeted α-particle therapy for oncologic applications.

AJR Am J Roentgenol. 2014 Aug;203(2):253-60. doi: 10.2214/AJR.14.12554.

A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.

Neuro Oncol. 2012 Oct;14(10):1239-53. doi: 10.1093/neuonc/nos211. Epub 2012 Sep 5.

A method to predict response of cell populations to cocktails of chemotherapeutics and radiopharmaceuticals: validation with daunomycin, doxorubicin, and the alpha particle emitter (210)Po.

Nucl Med Biol. 2012 Oct;39(7):954-61. doi: 10.1016/j.nucmedbio.2012.01.011. Epub 2012 Apr 14.

Preparation and in vivo evaluation of radioiodinated closo-decaborate(2-) derivatives to identify structural components that provide low retention in tissues.

Nucl Med Biol. 2010 Feb;37(2):167-78. doi: 10.1016/j.nucmedbio.2009.10.004.

Unconventional nuclides for radiopharmaceuticals.

Mol Imaging. 2010 Feb;9(1):1-20.

本文引用的文献

Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model.

Cancer Biol Ther. 2008 Jan;7(1):76-80. doi: 10.4161/cbt.7.1.5132. Epub 2007 Oct 8.

Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies.

Clin Cancer Res. 2008 Feb 1;14(3):875-82. doi: 10.1158/1078-0432.CCR-07-1250.

Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.

J Nucl Med. 2008 Jan;49(1):30-8. doi: 10.2967/jnumed.107.046938. Epub 2007 Dec 12.

Rational design and generation of a bimodal bifunctional ligand for antibody-targeted radiation cancer therapy.

J Med Chem. 2008 Jan 10;51(1):118-25. doi: 10.1021/jm070401q. Epub 2007 Dec 7.

Targeted alpha-therapy: past, present, future?

Dalton Trans. 2007 Nov 21(43):4918-28. doi: 10.1039/b704726f. Epub 2007 Sep 11.

Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.

Nucl Med Biol. 2007 Oct;34(7):779-85. doi: 10.1016/j.nucmedbio.2007.03.007. Epub 2007 May 11.

Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.

Nucl Med Biol. 2007 Oct;34(7):757-78. doi: 10.1016/j.nucmedbio.2007.04.001. Epub 2007 Jun 8.

Radioimmunotherapy with alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5604s-5612s. doi: 10.1158/1078-0432.CCR-07-1071.

Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice.

Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):572-9. doi: 10.1016/j.ijrobp.2007.06.023.

Biodistribution of 211At-labeled humanized monoclonal antibody A33.

Cancer Biother Radiopharm. 2007 Aug;22(4):480-7. doi: 10.1089/cbr.2007.349A.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Alpha-particle radioimmunotherapy with astatine-211 and bismuth-213.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献